Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its upcoming participation in two major investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will be featured in fireside chats at both events.
The schedule includes:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET
- Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET
Both presentations will be available via webcast on the company's website, accessible for at least 30 days following each event.
Caribou Biosciences (Nasdaq: CRBU), una società biofarmaceutica in fase clinica specializzata nell'editing genomico CRISPR, ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori. Rachel Haurwitz, PhD, presidente e CEO dell'azienda, sarà protagonista di conversazioni informali in entrambi gli eventi.
Il programma include:
- 3ª Conferenza Virtuale sulla Terapia Cellulare di H.C. Wainwright il 25 febbraio 2025, alle 11:30 ET
- Conferenza Globale sulla Salute di Leerink il 11 marzo 2025, alle 13:40 ET
Entrambe le presentazioni saranno disponibili tramite webcast sul sito web dell'azienda, accessibili per almeno 30 giorni dopo ciascun evento.
Caribou Biosciences (Nasdaq: CRBU), una empresa biofarmacéutica en etapa clínica especializada en la edición genómica CRISPR, ha anunciado su próxima participación en dos importantes conferencias para inversores. Rachel Haurwitz, PhD, presidenta y CEO de la compañía, participará en charlas informales en ambos eventos.
El calendario incluye:
- 3ª Conferencia Virtual de Terapia Celular de H.C. Wainwright el 25 de febrero de 2025, a las 11:30 AM ET
- Conferencia Global de Salud de Leerink el 11 de marzo de 2025, a la 1:40 PM ET
Ambas presentaciones estarán disponibles a través de webcast en el sitio web de la empresa, accesibles durante al menos 30 días después de cada evento.
Caribou Biosciences (Nasdaq: CRBU)는 임상 단계의 CRISPR 유전자 편집 생명공학 회사로, 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다. Rachel Haurwitz, PhD는 두 행사에서 화상 대담에 출연할 예정입니다.
일정은 다음과 같습니다:
- H.C. Wainwright 제3회 세포 치료 가상 회의는 2025년 2월 25일 오전 11시 30분 ET에 진행됩니다.
- Leerink 글로벌 헬스케어 회의는 2025년 3월 11일 오후 1시 40분 ET에 진행됩니다.
두 발표 모두 회사 웹사이트를 통해 웹캐스트로 제공되며, 각 행사 후 최소 30일 동안 접근할 수 있습니다.
Caribou Biosciences (Nasdaq: CRBU), une entreprise biopharmaceutique en phase clinique spécialisée dans l'édition génomique CRISPR, a annoncé sa prochaine participation à deux grandes conférences pour investisseurs. Rachel Haurwitz, PhD, la présidente et PDG de l'entreprise, sera présente lors de discussions informelles aux deux événements.
Le programme comprend :
- 3ème Conférence Virtuelle sur la Thérapie Cellulaire de H.C. Wainwright le 25 février 2025, à 11h30 ET
- Conférence Mondiale sur la Santé de Leerink le 11 mars 2025, à 13h40 ET
Les deux présentations seront disponibles par webdiffusion sur le site de l'entreprise, accessibles pendant au moins 30 jours après chaque événement.
Caribou Biosciences (Nasdaq: CRBU), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das auf CRISPR-Gentechnik spezialisiert ist, hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt. Rachel Haurwitz, PhD, die Präsidentin und CEO des Unternehmens, wird in beiden Veranstaltungen an informellen Gesprächen teilnehmen.
Der Zeitplan umfasst:
- 3. Virtuelle Zelltherapie-Konferenz von H.C. Wainwright am 25. Februar 2025 um 11:30 Uhr ET
- Leerink Global Healthcare Conference am 11. März 2025 um 13:40 Uhr ET
Beide Präsentationen werden über einen Webcast auf der Unternehmenswebsite verfügbar sein, der mindestens 30 Tage nach jeder Veranstaltung zugänglich ist.
- None.
- None.
BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 25, 2025, fireside chat at 11:30 AM ET
Webcast
- Leerink Global Healthcare Conference
March 11, 2025, fireside chat at 1:40 PM ET
Webcast
For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
When is Caribou Biosciences (CRBU) presenting at the H.C. Wainwright Cell Therapy Conference 2025?
What upcoming investor conferences will CRBU participate in during Q1 2025?
How long will the CRBU conference webcasts be available for viewing?
What time is Caribou Biosciences presenting at the Leerink Global Healthcare Conference 2025?
